Home »
Academic Articles »
R »
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
Katharina T. Prochazka
(Division of Hematology, Medical University of Graz, Austria)
Gudrun Pregartner
(Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria)
Frank G. Rücker
(Department of Internal Medicine III, University Hospital of Ulm, Germany)
Ellen Heitzer
(Institute of Human Genetics, Medical University of Graz, Austria)
Gabriel Pabst
(Division of Hematology, Medical University of Graz, Austria)
Albert Wölfler
(Division of Hematology, Medical University of Graz, Austria)
Armin Zebisch
(Division of Hematology, Medical University of Graz, Austria)
Andrea Berghold
(Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria)
Konstanze Döhner
(Department of Internal Medicine III, University Hospital of Ulm, Germany)
Heinz Sill
(Division of Hematology, Medical University of Graz, Austria)
Journal: Haematologica
•
• Ferrata Storti Foundation
• ISSN: 0390-6078
Abstract
The role of subclonal TP53 mutations, defined by a variant allele frequency of 40%, 20%-40% and 40%, 19 had variant allele frequencies between 20%-40% and 18 had frequencies
Katharina T. Prochazka, Gudrun Pregartner, Frank G. Rücker, et al. (2019). "Clinical implications of subclonal TP53 mutations in acute myeloid leukemia". Haematologica. https://doi.org/10.3324/haematol.2018.205013